Search research articles
Contact Us
Filters
Showing results (81-90 of 153) with videos related to
Page
of 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 12, 2024
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations
Kelsey Pan, Jennifer Owens, Yasir Elamin, et al.
American Journal of Clinical Oncology
|
October 30, 2024
The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity
Jay Shah, Andres Caleb Urias Rivera, Irene Jeong-Ah Lee, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2020
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
Joao V Alessi, Biagio Ricciuti, Elizabeth Jiménez-Aguilar, et al.
Diseases of the Colon and Rectum
|
December 17, 2019
Neutropenic Enterocolitis: Clinical Features and Outcomes
Hamzah Abu-Sbeih, Faisal S Ali, Ellie Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 4, 2021
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer
Jake S Jacob, Barbara E Dutra, Victor Garcia-Rodriguez, et al.
Journal of Cancer Research and Clinical Oncology
|
November 2, 2023
Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors
Gabriel Sperling, Malek Shatila, Krishnavathan Varatharajalu, et al.
Journal of Cancer Research and Clinical Oncology
|
October 15, 2022
Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies
Austin R Thomas, Mostafa Eyada, Miho Kono, et al.
Journal for Immunotherapy of Cancer
|
December 25, 2024
High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC
Mehmet Altan, Ruoxing Li, Ziyi Li, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 13, 2025
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma
Felipe Soto, Ugochi Ebinama, William P Brasher, et al.
Clinical Lung Cancer
|
February 26, 2022
Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer
Mehmet Altan, Eric K Singhi, Michelle Worst, et al.
Page
of 16
Search research articles
Search
Showing results (81-90 of 153) with videos related to
Sort By:
Page
of 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 12, 2024
Mutational Characteristics and Clinical Outcomes for Lung Adenocarcinoma With EGFR Germline Mutations
Kelsey Pan, Jennifer Owens, Yasir Elamin, et al.
American Journal of Clinical Oncology
|
October 30, 2024
The Effect of PD-1/PD-L1 Inhibitor and Statin Combination Therapy on Overall Survival and Gastrointestinal Toxicity
Jay Shah, Andres Caleb Urias Rivera, Irene Jeong-Ah Lee, et al.
Journal for Immunotherapy of Cancer
|
August 6, 2020
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non-small cell lung cancer and a poor performance status
Joao V Alessi, Biagio Ricciuti, Elizabeth Jiménez-Aguilar, et al.
Diseases of the Colon and Rectum
|
December 17, 2019
Neutropenic Enterocolitis: Clinical Features and Outcomes
Hamzah Abu-Sbeih, Faisal S Ali, Ellie Chen, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 4, 2021
Clinical Characteristics and Outcomes of Oral Mucositis Associated With Immune Checkpoint Inhibitors in Patients With Cancer
Jake S Jacob, Barbara E Dutra, Victor Garcia-Rodriguez, et al.
Journal of Cancer Research and Clinical Oncology
|
November 2, 2023
Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors
Gabriel Sperling, Malek Shatila, Krishnavathan Varatharajalu, et al.
Journal of Cancer Research and Clinical Oncology
|
October 15, 2022
Characteristics, treatment, and outcome of diverticulitis after immune checkpoint inhibitor treatment in patients with malignancies
Austin R Thomas, Mostafa Eyada, Miho Kono, et al.
Journal for Immunotherapy of Cancer
|
December 25, 2024
High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC
Mehmet Altan, Ruoxing Li, Ziyi Li, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
June 13, 2025
Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Relapsed or Refractory Lymphoma
Felipe Soto, Ugochi Ebinama, William P Brasher, et al.
Clinical Lung Cancer
|
February 26, 2022
Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer
Mehmet Altan, Eric K Singhi, Michelle Worst, et al.
Page
of 16